ALX Oncology Holdings Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging -3.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.15 | $-0.13 | +13.3% | Beat | |
| Q1 FY26 | $-0.15 | $-0.17 | -13.3% | Miss | Q1 FY26 call |
| Q4 FY25 | $-0.38 | $-0.42 | -10.5% | Miss |
Back to ALXO overview · ALXO holders · ALXO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.